Vogenx Inc (NASDAQ:VOGX – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 14th, there was short interest totaling 25,591 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average daily trading volume, of 69,269 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company’s shares are short sold.
Vogenx Stock Performance
Shares of VOGX opened at $33.96 on Monday. Vogenx has a 12-month low of $12.95 and a 12-month high of $35.50.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Vogenx to a “hold” rating in a research note on Saturday, August 22nd.
About Vogenx
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
Featured Stories
- Five stocks we like better than Vogenx
- Broadcom’s Earnings Test Comes With a Higher Bar After NVIDIA’s Blowout
- Palo Alto’s Rally Has One Big Problem Ahead of Earnings
- These 5 ETFs Have Raked in Cash This Year—What Do They All Have in Common?
- DLocal Is Testing the Breakout Level That Could Change Its Stock Story
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
